RxDoctor Payments Data

David Colon Golderos, MD

General Practice · Rio Grande, PRNPI 1114926342

Payments from drug & device makers

$2,662in general payments, 2019–2025

Across 68 payments — averaging $39.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$559
  • Boehringer Ingelheim$511
  • E.r. Squibb & Sons, L.L.C.$349
  • Johnson & Johnson$271
  • Lilly USA, LLC$227
  • Novo Nordisk$165
  • plus $581 from 7 others

What the payments were for

  • Food & beverage$2,662100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca11$559
Boehringer Ingelheim18$511
E.r. Squibb & Sons, L.L.C.4$349
Johnson & Johnson9$271
Lilly USA, LLC2$227
Novo Nordisk3$165
Sanofi-aventis U.S. LLC8$156
GSK1$123
Pfizer Pharmaceuticals LLC2$109
PBG Puerto Rico LLC5$98
AbbVie2$43
Merck2$40
Biohaven Pharmaceutical Holding Company Ltd.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,662 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$2,622
Medicare patients
13
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol119$98,547
EliquisApixaban112$95,828
Trijardy XrEmpaglifloz/Linaglip/Metformin78$55,677
TradjentaLinagliptin71$55,508
XareltoRivaroxaban63$50,735
SynthroidLevothyroxine Sodium413$37,850
JardianceEmpagliflozin44$31,634
LantusInsulin Glargine,hum.Rec.Anlog251$29,315
EntrestoSacubitril/Valsartan33$28,334
JanumetSitagliptin Phos/Metformin Hcl40$28,020
GlyxambiEmpagliflozin/Linagliptin27$24,970
Soliqua 100-33Insulin Glargine/Lixisenatide26$23,020
MounjaroTirzepatide21$22,142
Candesartan Cilexetil218$20,886
Synjardy XrEmpagliflozin/Metformin Hcl20$20,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTrijardy Xr, Tradjenta, Jardiance, Glyxambi, Synjardy Xr$511$245,605360 claims
AstraZenecaFarxiga$559$98,547119 claims
Sanofi-aventis U.S. LLCLantus, Soliqua 100-33$156$52,335277 claims
Johnson & JohnsonXarelto$271$50,73563 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30$227$49,610121 claims
AbbVieSynthroid, Lumigan$43$47,174447 claims
MerckJanumet, Januvia$40$39,88556 claims
GSKTrelegy Ellipta, Breo Ellipta$123$28,29947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Rio Grande

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →